Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 2
2009 1
2010 2
2012 1
2013 1
2014 1
2015 1
2016 1
2018 2
2019 3
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed (GeneRIF) for id: 951

18 results

Results by year

Filters applied: . Clear all
Page 1
CD37 expression in follicular lymphoma.
Yoshimura T, Miyoshi H, Shimono J, Nakashima K, Takeuchi M, Yanagida E, Yamada K, Shimasaki Y, Moritsubo M, Furuta T, Kohno K, Ohshima K. Yoshimura T, et al. Ann Hematol. 2022 May;101(5):1067-1075. doi: 10.1007/s00277-022-04785-z. Epub 2022 Feb 16. Ann Hematol. 2022. PMID: 35171311
High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.
Elfrink S, de Winde CM, van den Brand M, Berendsen M, Roemer MGM, Arnold F, Janssen L, van der Schaaf A, Jansen E, Groenen PJTA, Eijkelenboom A, Stevens W, Hess CJ, van Krieken JH, Vermaat JSP, Cleven AHG, de Groen RAL, Neviani V, de Jong D, van Deventer S, Scheijen B, van Spriel AB. Elfrink S, et al. Blood. 2019 Sep 19;134(12):946-950. doi: 10.1182/blood.2019001185. Epub 2019 Jul 31. Blood. 2019. PMID: 31366619 Free PMC article.
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
Stilgenbauer S, Aurran Schleinitz T, Eichhorst B, Lang F, Offner F, Rossi JF, Schroyens W, Van Den Neste E, Ysebaert L, von Wangenheim U, Ursula Kress U, Blum P, Zenz T. Stilgenbauer S, et al. Leukemia. 2019 Oct;33(10):2531-2535. doi: 10.1038/s41375-019-0475-z. Epub 2019 May 14. Leukemia. 2019. PMID: 31089249 Free article. Clinical Trial. No abstract available.
Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial.
Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J. Dohm A, et al. Int J Biol Markers. 2019 Mar;34(1):90-97. doi: 10.1177/1724600818803104. Epub 2019 Mar 10. Int J Biol Markers. 2019. PMID: 30854931 Free PMC article.
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH. Xu-Monette ZY, et al. Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19. Blood. 2016. PMID: 27760757 Free PMC article.
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. Pereira DS, et al. Mol Cancer Ther. 2015 Jul;14(7):1650-60. doi: 10.1158/1535-7163.MCT-15-0067. Epub 2015 May 1. Mol Cancer Ther. 2015. PMID: 25934707 Free PMC article.
18 results